Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00618488 · ClinicalTrials.gov registry record · NA

Efficacy of Yogurt Containing BB12 in Subjects With GI Symptoms

A NA study, sponsored by University of North Carolina.

Completed
Registry status
NA
Development phase
63
Enrollment target

NCT00618488: Completed NA study, sponsored by University of North Carolina.

NCT00618488 is a NA study that has completed, run by University of North Carolina. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00618488, a NA study, has completed, sponsored by University of North Carolina.

COMPLETED
Registry status
NA
Development phase
63 participants
Enrollment target

Study Summary

The purpose of this study is to determine if probiotics bacteria, specifically bifidobacterium lactis (BB12) improve gastrointestinal symptoms in subjects with functional gastrointestinal symptoms (i.e., non-patients IBS/functional bowel disorders).

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Probiotic BB12 - Bifidobacterium lactis

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2007-02
Est. Completion 2007-11
Phase NA
University of North Carolina

14 total trials

What the finished NCT00618488 record still lists

NCT00618488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00618488 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00618488 about?

NCT00618488 is a clinical study titled "Efficacy of Yogurt Containing BB12 in Subjects With GI Symptoms". The purpose of this study is to determine if probiotics bacteria, specifically bifidobacterium lactis (BB12) improve gastrointestinal symptoms in subjects with functional gastrointestinal symptoms (i.e., non-patients IBS/functional bowel disorders).

What is the current status of trial NCT00618488?

This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2007-02. Estimated completion is 2007-11.

What interventions are being tested in trial NCT00618488?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Probiotic BB12 - Bifidobacterium lactis (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00618488?

This trial is sponsored by University of North Carolina, which has 14 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00618488's enrollment target sits among peer trials

63 1157th of 2000 higher than 844 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00618488, the US trial registry maintained by the National Library of Medicine. NCT00618488 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.